WHO Backs Pfizer’s Paxlovid For High-Risk COVID-19 Patients
But Access Obstacles Remain In Lower-Income Countries
Executive Summary
An international group of experts has issued new guidance on the use of therapeutics in patients with non-severe COVID-19.
You may also be interested in...
Global COVID-19 Access Program Facing ‘Financial Crisis’
ACT-A, an initiative led by the World Health Organization and involving international health agencies, has significantly improved access to COVID-19 medical countermeasures in lower-income countries. However, further progress could be hindered by a funding shortfall, and ACT-A has urged donors to contribute their fair share.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.
EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’
Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.